Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers ; volume:14 ; number:1 ; day:7 ; month:8 ; year:2014 ; pages:1-14 ; date:12.2014
BMC cancer ; 14, Heft 1 (7.8.2014), 1-14, 12.2014
- Creator
-
Bryant, Christopher
- Contributor
-
Rawlinson, Rebecca
Massey, Andrew J.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-14-570
- URN
-
urn:nbn:de:1111-2016030417651
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bryant, Christopher
- Rawlinson, Rebecca
- Massey, Andrew J.
- SpringerLink (Online service)
Other Objects (12)
Classification of triple-negative breast cancers based on Immunogenomic profiling
Targeting a cell state common to triple‐negative breast cancers
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
Molecular characterisation of cell line models for triple-negative breast cancers
A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers
Comparative characterization of 3D chromatin organization in triple-negative breast cancers
HPV infection and triple-negative breast cancers: an Italian case-control study
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers
The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers
Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival
Classification of triple-negative breast cancers based on Immunogenomic profiling
Targeting a cell state common to triple‐negative breast cancers
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
Molecular characterisation of cell line models for triple-negative breast cancers
A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers
Comparative characterization of 3D chromatin organization in triple-negative breast cancers
HPV infection and triple-negative breast cancers: an Italian case-control study
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers
The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers
Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival
Classification of triple-negative breast cancers based on Immunogenomic profiling
Targeting a cell state common to triple‐negative breast cancers
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
Molecular characterisation of cell line models for triple-negative breast cancers
A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers
Comparative characterization of 3D chromatin organization in triple-negative breast cancers
HPV infection and triple-negative breast cancers: an Italian case-control study
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers
The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers